InBioGen Co Ltd (101140) — Cash Flow-to-Debt Ratio
InBioGen Co Ltd (101140) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of ₩-1.67 Billion could theoretically repay -1% of its total liabilities (₩2.44 Billion) in one year. See how financially flexible is InBioGen Co Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
InBioGen Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for InBioGen Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see InBioGen Co Ltd (101140) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for InBioGen Co Ltd (2013–2024)
Year-by-year debt coverage analysis for InBioGen Co Ltd. Check InBioGen Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-33.13 Million | ₩2.89 Billion | ▲ +97.1% |
| 2023 | -0.40x | ₩-1.05 Billion | ₩2.62 Billion | ▼ -30.3% |
| 2022 | -0.31x | ₩-11.51 Billion | ₩37.40 Billion | ▼ -319.7% |
| 2021 | -0.07x | ₩-7.07 Billion | ₩96.45 Billion | ▲ +82.7% |
| 2020 | -0.42x | ₩-8.03 Billion | ₩18.97 Billion | ▼ -175.6% |
| 2019 | -0.15x | ₩-3.83 Billion | ₩24.92 Billion | ▲ +91.2% |
| 2018 | -1.75x | ₩-1.70 Billion | ₩968.80 Million | ▼ -749.2% |
| 2017 | -0.21x | ₩-426.44 Million | ₩2.07 Billion | ▼ -496.8% |
| 2016 | 0.05x | ₩344.75 Million | ₩6.62 Billion | ▲ +103.2% |
| 2015 | -1.62x | ₩-10.96 Billion | ₩6.76 Billion | ▼ -595.5% |
| 2014 | -0.23x | ₩-695.95 Million | ₩2.99 Billion | ▼ -30.4% |
| 2013 | -0.18x | ₩-1.13 Billion | ₩6.33 Billion | — |